- Before
- Pieces together who owns which question and chases drafts while the agency clock runs.
- Now
- Opens a request already split, owned and drafted; signs each answer after its owner reviews it.
One FDA information request, from letter to signed answers
On October 6 the FDA sends twelve questions on the Veltrimab biologics license application, BLA 761904, with a response due October 16. Here is what happens next, screen by screen, in the working solution.
- 01Oct 6
Every open agency clock, on one screen
Dr. Maya Chen · Regulatory leadMaya opens the solution and sees where every request stands: 9 open requests from 7 agencies across 3 products, 129 questions still open, 5 answers reviewed by owners and waiting for her signature. The newest clock is the FDA’s on Veltrimab: 10 days, due Oct 16.
Consistency checks: “Shelf life — Veltrimab prefilled syringe · Swissmedic draft says 18 months · FDA answer confirms 24 months.”
- 0208:12
The letter arrives from the FDA portal mailbox
Dr. Maya Chen · Regulatory leadIR_BLA761904_2026-10-06.pdf arrives on its own from the FDA portal mailbox. Maya reads it in the solution: product quality questions on host cell protein, stability, leachables and hold times, then clinical pharmacology, immunogenicity, clinical efficacy, safety, labeling and statistics — “We request a written response by Oct 16, 2026.”
- 03One click
“Split and assign” — and the agents start
The agentsThe agents read the four-page letter, split it into 12 numbered questions under 7 review headings, assign 7 owners from the approval rules, find 16 passages in Modules 2, 3 and 5 and 7 related past answers, and draft every answer. Then they check each draft against earlier answers and start the response clock, with reminders at 5, 3 and 1 days.
“12 drafts · 24 citations · every number cited.”
- 04By 15:40
Twelve questions, each with an owner and a stage
The question ownersEach question in the letter is now tagged Q1 to Q12, and the due date is highlighted. The tracker shows who owns what: Sam Patel for CMC, Lena Ortiz for clinical pharmacology, Dr. Priya Raman for immunogenicity, Dana Okafor for safety. By mid-afternoon 8 of 12 are approved; question 4 waits on Plant 3 — Leiden for hold-time data.
- 05Owner review
Question 7, drafted from the dossier
Dr. Priya Raman · Bioanalytical & immunogenicityThe FDA asks for the ADA and neutralizing antibody incidence through Week 52 of Study VLT-302, the impact on PK, PASI 75 and safety, and the drug tolerance of the assay. The draft answers every part with five sources cited — 31 of 642 patients (4.8%) with treatment-emergent ADA, 9 (1.4%) with neutralizing antibodies — and reuses the EMA answer of Jul 30. At 13:52 Priya changes “no impact” to “no hypersensitivity event was associated”, and at 14:20 she marks it reviewed.
“Covers every part: ADA and NAb incidence · Effect on PK · Effect on efficacy · Effect on safety · Assay drug tolerance.”
- 06Before signing
Every number opens at its passage
Dr. Maya Chen · Regulatory leadMaya clicks the first citation. The Integrated Summary of Immunogenicity opens at Module 5.3.5.3, §4.2, Table 6, page 14, with the sentence the number comes from highlighted — the same passage the FDA can read in the dossier.
- 07Flagged
A different data cut, caught before it is sent
Consistency checkerThe consistency checker has flagged what nobody went looking for: Health Canada was told 4.6% on Aug 21, 2026 from the Week 40 interim cut. This draft uses the Week 52 cut, the same as the EMA answer. Both numbers are right — so Maya adds a one-line data-cut note, and the check turns green: consistent with 3 earlier answers.
Added to the answer: “All figures use the Week 52 data cut (database lock March 14, 2026); our response to Health Canada of August 21, 2026 used the Week 40 interim cut (4.6%, 29 of 630 patients).”
- 08Signed
The regulatory lead signs the answer
Dr. Maya Chen · Regulatory leadMaya signs question 7 with her name and password. The meaning of the signature — “I approve this answer for submission to the agency” — is recorded in the audit trail with the date, the time and this version of the answer. The request moves to 9 of 12 approved, and Ruth Mensah is told that question 11, the labeling change that depends on it, can now be finalized.
- 09Package view
The response package, built from signed answers only
Package assemblerThe package for eCTD sequence 0012 lays out the cover letter (drafted when the package is built), the question-by-question response in the agency’s order, the attachments and the eCTD sequence details mapped to sections. At 8 of 12 answers signed, 5 of 7 attachments are ready; it shows what it still waits on: question 4 (hold-time data) and question 12 (tipping-point tables).
“Built only from signed answers. You sign the package before regulatory operations sends it.”
- 10Last 90 days
Every clock met, no conflicting answer sent
Dr. Maya Chen · Regulatory leadOver the last 90 days: 412 questions answered across 7 agencies, 13 of 13 responses on time, a median of 3.9 hours to first draft, and no conflicting answer sent — 27 caught by the consistency checker first. Owners changed 14% of drafted sentences before signing.